Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Department of Pathology and Laboratory Medicine, Division of Clinical Microbiology, and Department of Medicine, Division of Infectious Diseases, Evanston Northwestern Healthcare and Northwestern University, Evanston, IL 60201,USA. lancer@northwestern.edu
Therapy of infections caused by extended-spectrum beta-lactamase (ESBL)-producing bacteria with an antimicrobial to which they are resistant results in treatment failure, higher cost and increased mortality. The CLSI recommends reporting ESBL-producing strains of Escherichia coli, Klebsiella spp. and Proteus spp. as resistant to all penicillin, true cephalosporin and monobactam antimicrobials, but as susceptible to beta-lactam-beta-lactamase inhibitor combinations, including piperacillin-tazobactam, when they test as such. Current literature supports the action of piperacillin-tazobactam against susceptible strains of ESBL-producing bacteria based on the structure-activity relationship between inhibitors and the ESBLs, as well as on recent clinical outcome studies.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on